The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be presented at the upcoming American Heart Association (AHA) Scientific Sessions […]
WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial have been selected for a poster presentation […]
COPENHAGEN, Denmark, November 5, 2018 /PRNewswire/ — – Phase 1 data show favourable safety profile – Data support further development of AP30663 for cardioversion therapy Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its […]
WILMINGTON, Mass., Nov. 5, 2018 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions designed to improve clinical outcomes and quality of life, announced today that it has received CE Mark approval for a 4Fr.-compatible MicroStent 120 cm delivery catheter, as well as MicroStent devices in five […]
TRONDHEIM, Norway–(BUSINESS WIRE)–CardioMech AS announced today that it has appointed Richard Nehm as President and CEO, and Mark Novotny as Chairman of the Board of Directors, effective immediately. Rick and Mark join the company alongside founders Jacob Bergsland, Chief Medical Officer, and Nikolai Hiorth, Chief Technology Officer. Rick Nehm is a seasoned medical device professional in the […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2018 financial results. “We are pleased with our third quarter performance and building track record of strong, consistent, revenue growth,” said Mike Carrel, President and Chief […]
NAARDEN, Netherlands, & MUNICH–(BUSINESS WIRE)–Forbion, a leading European life science venture capital firm, today announces that it has led a €17m Series C financing of OMEICOS Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin, Germany. Forbion is the only new investor participating in the financing round, contributing €12.5m […]
ST. LOUIS, Nov. 02, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018 on Monday, November 12, 2018 before the open […]
BASKING RIDGE, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and nine months ended September 30, 2018 […]
SUWANEE, Ga., Nov. 02, 2018 (GLOBE NEWSWIRE) — Digirad Corporation (Nasdaq: DRAD) today reported its financial results for the third quarter and nine months ended September 30, 2018. Total revenues from continuing operations for the third quarter were $25.7 million, compared to $25.8 million in the third quarter of the prior […]
